Syngene International Limited

Watch our MD and CEO, Jonathan Hunt, in an exclusive interview with NDTV Profit as he discusses Syngene’s performance during the second quarter, covering key topics such as the US biotech funding landscape, recovery in discovery research, biologics manufacturing, and the company’s capital expenditure plans. Speaking on US biotech funding, Jonathan noted, “The first half of the year saw stabilization in new capital formation for US biotech. We are beginning to see improvement in the biotech-driven discovery research environment. While it may be early to call this a structural shift, it represents a stable and healthy indication of recovery.” Read our press release 👉 https://lnkd.in/gFi9z_P5 #Syngene #Q2FY25Results #ChinaPlusOne #NDTVProfit

We are excited to attend #AusBiotech in Melbourne, Australia, from October 30 to November 1, 2024. Meet our team at the conference to discuss how Syngene can help accelerate your R&D programs. Book a meeting now 👉 Link in the comments section. We are a full-service CRO and CDMO serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. We offer end-to-end discovery, development, and manufacturing services across small molecules and biologics. #drugdiscovery #drugdevelopment

We are excited to attend the World ADC San Diego 2024 from November 4-7, 2024 in San Diego, CA. Meet our expert at booth #101 to discuss how we can support your Antibody-Drug Conjugates related projects. Book a meeting now 👉 Link in the comments section.

Catch our MD and CEO, Jonathan Hunt, in an insightful conversation with ET Now, where he shares Syngene’s Q2 and H1FY25 performance highlights and provides an outlook for the second half of the financial year. Jonathan discusses Syngene’s strategic growth drivers, including the "China plus one" strategy and the increase in client visits, which are setting a strong foundation for sustained growth over the next 3-5 years. He also shares exciting progress on Syngene’s new biologics manufacturing facility. Watch the full interview. Read our press release here 👉 https://lnkd.in/ghwPPjDQ  #Syngene #Q2Results #ChinaPlusOne #ETNow

We are excited to attend BIO EUROPE in Stockholm, Sweden from November 4-6, 2024. Connect with our experts to discuss how Syngene can assist you in accelerating your R&D programs across small molecules and biologics.   Book a meeting now 👉  Link in the comments.   Syngene is a full-service CRO and CDMO serving the global pharmaceutical, biotechnology, and animal health sectors. We offer end-to-end #drugdiscovery, #drugdevelopment, and #drugmanufacturing services across small molecules and biologics. Our culture of scientific innovation is driven by the expertise of our highly qualified team of 6000+ scientists and supported by state-of-the-art infrastructure and market-leading technology.   #BIOEurope2024 #CDMO #Biologics

Enantioselective cyclopropanation remains a significant task in the field of Organic chemistry. At Syngene, we tackled this head-on by employing multiple chemical strategies, successfully producing over 800 Kg of the regulatory starting material (RSM). This achievement underscores our commitment to innovation and excellence in overcoming synthesis and scale-up challenges related to the safe and efficient usage of Diethylzinc reagent. Read the article co-published with our customer in the American Chemical Society's OPRD journal 👉 https://lnkd.in/grCeJTkY #Syngene #Pharmaceuticals #Innovation #GMP #ChemicalDevelopment

Our team of seasoned experts provides comprehensive, customized in vivo PK solutions tailored to each client's unique research needs under the guidance of Dr. Amol Raje, Assistant Director. With a commitment to the highest ethical standards, our strong capabilities generate high-quality data that accelerates drug discovery projects and ensures reliable results.   Syngene's Preclinical Pharmacokinetic Research services are crafted to meet globally accepted protocols. Studies are conducted in world-class facilities to accelerate drug discovery and development, facilitating timely decision-making. Investigators have access to over 190 assays in our catalog to advance their molecules to the next stage. Vishwottam Kandikere, PhD, Head of DMPK, shares that these studies leverage best experimental practices to generate robust and dependable data.   Partnering with us means leveraging our scientific excellence, innovative approach, and unwavering commitment to delivering impactful results. Global biopharma leaders trust Syngene to advance their pipeline with precision and speed.   #InVivoDMPK #SyngeneDrugDiscovery #DMPK

Our latest case study on BioPharma Dive showcases how Syngene’s platform approach successfully addressed low yields and lengthy processes, achieving a four-fold increase in titer production. This enabled the creation of high-quality clones optimized for mAb manufacturing within a shorter timeframe. Read now 👉 link in the comments section. #mAb #Syngene #CRDMO

Syngene announces Q2FY25 results. Link to the press release 👉 https://lnkd.in/ghwPPjDQ #Q2FY25 #Syngene #Pressrelease

We’re thrilled to announce that Syngene has been recognized in the 4th edition of Business World magazine’s India’s Most Sustainable Companies (IMSC)!    Out of the top 250 companies assessed across 17 sectors, we ranked 91st overall based on 36 key performance indicators related to environmental, social, and governance (ESG) factors.   In the Pharmaceutical sector, we are proud to share that Syngene ranked 9th out of 26 companies evaluated, making us the only CRDMO featured in the top 10!  Thank you to our incredible team and partners for making this achievement possible! Together, we’re driving innovation and sustainable practices in the biopharma industry. Read Syngene's latest ESG Report 👉 link in the comments section.   #Sustainability #Syngene #Pharmaceuticals #Innovation